Donald Brydon to become chairman of MRC on 1 October

The appointment is for four years

Donald Brydon has been welcomed to the UK’s Medical Research Council (MRC) as chairman. He will succeed Sir John Chisholm on 1 October. The appointment is for four years.

Brydon has been chairman of the Royal Mail Group since 2009. He has also been chairman of Smiths Group since 2004, chaired the London Metal Exchange from 2003–2010, and was a director of AXA Investment Managers (1997–2012).

Brydon will become chairman of Sage Group from 1 September. He also spent nearly 20 years in the Barclays Group (1977–1996), particularly in BZW Investment Management (1986–94), and was deputy chief executive BZW from 1994–96.

You may also like

Drug Delivery

Catapult and MRC unite to advance human-based drug evaluation

Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool announce strategic collaboration to develop next generation human cell models
Ingredients

£12 million in grants to tackle superbugs in a global context

The researchers will use a range of approaches, from clinical and microbiological to geography, modelling and social sciences, to identify, prioritise and understand the specific problem of AMR across different communities and environments in Kenya, Tanzania, Uganda, Malawi and Thailand
Media

MRC forges two new deals with industry to speed drug discovery

Building on the MRC’s strong track record in establishing innovative collaborations with industry, the MRC has formed partnerships with two global pharmaceutical companies, UCB and AstraZeneca
Research & Development

Scientists uncover tau filament structures from Alzheimer’s

Researchers at the Medical Research Council Laboratory of Molecular Biology have, for the first time, revealed the atomic structures of one of the two types of the abnormal filaments, which lead to Alzheimer's disease
Ingredients

Alzheimer’s advance: early stage study in mice show new drugs that restore memory loss and prolong life

Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration
Recruitment

Director announced to lead UK Dementia Research Institute in London

The director of the UK Dementia Research Institute (UK DRI) has been named as Professor Bart De Strooper, current leader of the Laboratory for the Research of Neurodegenerative Diseases at the University of Leuven and scientific director at VIB (Vlaams Instituut voor Biotechnologie) in Belgium. Professor De Strooper will lead the national institute from UCL
Research & Development

Genetic approach could help identify side-effects at early stages of drug development

Involves identifying genetic variants that mimic the action of a drug on its intended target and then checking in large patient groups whether these variants are associated with risk of other conditions
Subscribe now